Biotech Values

[flatlander_60048]

Let me see Pfe with shrinking Revs and R&D cuts at a PE of 9 or NVS with double digit rev growth and a 1.5% increase in R&D and a PE of 10. I'll take NVS but you can argue that they both are way undervalued. Both will benefit from the emerging market tailwind. NVS also benefits by being more diverse with better growth from Alcon, biogenerics and vaccines.



FL